New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
0

Hyperkalaemia on the surgical ward

A 56 year old woman was admitted with an infected stump wound at the site of a below the knee amputation. Her medical history included type 2 diabetes, diabetic foot ulcer, and painful peripheral neuropathy. Her regular drugs were metformin, amitriptyline, lansoprazole, Humulin I and Novorapid SC insulin, aspirin, paracetamol, morphine sulfate, gabapentin, and carbamazepine. In hospital, she was also prescribed dalteparin 5000 units subcutaneously once daily, intravenous benzylpenicillin, and flucloxacillin.  
feeds.bmj.com
almost 5 years ago
Preview
0
0

Hyperkalaemia on the surgical ward

A 56 year old woman was admitted with an infected stump wound at the site of a below the knee amputation. Her medical history included type 2 diabetes, diabetic foot ulcer, and painful peripheral neuropathy. Her regular drugs were metformin, amitriptyline, lansoprazole, Humulin I and Novorapid SC insulin, aspirin, paracetamol, morphine sulfate, gabapentin, and carbamazepine. In hospital, she was also prescribed dalteparin 5000 units subcutaneously once daily, intravenous benzylpenicillin, and flucloxacillin.  
feeds.bmj.com
almost 5 years ago
Preview
0
0

Insulin Analysis of ACCORD Published: Dose Not Linked to CV Death

In a post hoc analysis of the ACCORD trial, insulin dose was higher among those with cardiovascular death, but the association disappeared after adjustment for multiple confounders.  
medscape.com
almost 5 years ago
Preview
0
1

Premixed Human Insulin Ups Inpatient Hypoglycemia Rate in T2D

Use of premixed NPH/regular insulin produced threefold higher rates of hypoglycemia compared with glargine/glulisine in hospitalized patients with type 2 diabetes.  
medscape.com
almost 5 years ago
Preview
0
0

Sitagliptin vs Mitiglinide Switched From Insulin in T2D

A new study examines the feasibility and efficacy of substituting these oral hypoglycemic agents for insulin therapy in patients with type 2 diabetes.  
medscape.com
almost 5 years ago
Preview
0
0

The Double Jeopardy of Subcutaneous Insulin in Diabetes

In this commentary, the author discusses the effects of subcutaneous insulin delivery and the potential implications of this insulin therapy in diabetes.  
medscape.com
almost 5 years ago
Preview
1
8

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) | key-points-from-the-evidence | Advice | NICE

High‑strength insulin products such as insulin glargine 300 units/ml (Toujeo) have been developed for people with large daily insulin requirements to reduce the number and volume of injections. In 1 randomised controlled trial (RCT) in 549 people with type 1 diabetes, Toujeo had similar efficacy to insulin glargine 100 units/ml (Lantus) in terms of HbA1c reduction, but the basal insulin dose used was higher with Toujeo than with Lantus. There was no benefit of Toujeo over Lantus in terms of reduced hypoglycaemic events. The safety profile of Toujeo is largely similar to that of Lantus. Toujeo is not bioequivalent to Lantus and they are not interchangeable without dose adjustment.  
nice.org.uk
almost 5 years ago
Preview
1
1

Type 1 diabetes: insulin degludec | key-points-from-the-evidence | Advice | NICE

The long-acting insulin analogue, insulin degludec, is available in 2 strengths: 100 units/ml and 200 units/ml. It is non-inferior to insulin glargine in terms of glycaemic control in type 1 diabetes, with statistically significantly lower rates of nocturnal hypoglycaemia. Although there is one published 104 week study reporting some safety data, there are no published studies comparing insulin degludec with NPH (isophane) insulin and none that measure patient-oriented efficacy outcomes.  
nice.org.uk
almost 5 years ago
Preview
1
0

Type 2 diabetes: insulin degludec | Key-points-from-the-evidence | Advice | NICE

The long-acting insulin analogue, insulin degludec, is available in 2 strengths: 100 units/ml and 200 units/ml. It is non-inferior to insulin glargine in terms of glycaemic control in type 2 diabetes, with statistically significantly lower rates of some, but not all, measures of hypoglycaemia, particularly nocturnal hypoglycaemia. Although there are published studies with one year data, there are none comparing insulin degludec with NPH (isophane) insulin and none that measure patient-oriented efficacy outcomes.  
nice.org.uk
almost 5 years ago
Preview
1
19

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) | Key-points-from-the-evidence | Advice | NICE

In people who are insulin-naïve, insulin degludec/liraglutide (Xultophy) was non‑inferior to insulin degludec alone and superior to liraglutide alone for reductions in HbA1c (with a difference of 0.64% compared with liraglutide). In people previously treated with basal insulin, insulin degludec/liraglutide was superior to insulin degludec alone for reducing HbA1c with a difference of 1.1%. The safety profile and long‑term safety concerns of insulin degludec/liraglutide are broadly in line with those of the 2 included components.  
nice.org.uk
almost 5 years ago
Preview
1
1

Type 2 diabetes: lixisenatide | Key-points-from-the-evidence | Advice | NICE

The glucagon-like peptide-1 (GLP-1) mimetic lixisenatide is more effective than placebo in reducing glycated haemoglobin (HbA1c) in people with type 2 diabetes who are receiving oral antidiabetic drugs or basal insulin. Non-inferiority to exenatide has not been shown robustly for this outcome. There are no published data relating to patient-oriented outcomes or long-term safety.  
nice.org.uk
almost 5 years ago
Preview
0
0

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)

Study question What are the effects of liraglutide, an incretin based treatment, on glycaemic control in people with type 2 diabetes treated with multiple daily insulin injections?  
feeds.bmj.com
almost 5 years ago
Preview
0
0

Applying the Fundamentals of Insulin Physiology to Build a Better Insulin: Highlights From AACE and ADA CME

This activity is intended for diabetologists, endocrinologists, certified diabetes educators, and other healthcare professionals who have an interest in normal insulin physiology, key differences in endogenous and exogenous insulin secretion, nonphysiologic regulation of other metabolic functions of insulin, the relationship between insulin and peripheral tissues, and current and emerging insulin preparations.  
medscape.org
almost 5 years ago
Preview
0
0

The Future of Insulin Therapy: Why Change Is Necessary CME

This activity is intended for diabetologists and endocrinologists, primary care physicians, and other healthcare professionals who treat patients with type 2 diabetes.  
medscape.org
almost 5 years ago
Preview
0
1

Patient Demographics and Insulin Use in 18 Countries

How does insulin use among type 2 diabetes patients vary between countries, and what factors may influence treatment regimens? Data from a large international study sheds some light.  
medscape.com
almost 5 years ago
Preview
0
2

Add-on Liraglutide Fails to Improve HbA1c in Type 1 Diabetes

Liraglutide add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes fails to improve hemoglobin A1c (HbA1c), according to new research.  
medscape.com
almost 5 years ago
Preview
0
0

High-Sugar/Fat Diet Tied to High Insulin, Subsequent Hypertension

A "sweets/fat diet" and a Southern diet (high in sugar) were linked with greater odds of having high fasting insulin and, in turn, hypertension and left ventricular hypertrophy.  
medscape.com
almost 5 years ago
Preview
0
0

Critical Care

Although standard enteral nutrition is universally accepted, the use of disease-specific formulas for hyperglycemic patients is still controversial. This study examines whether a high-protein diabetes-specific formula reduces insulin needs, improves glycemic control and reduces ICU-acquired infection in critically ill, hyperglycemic patients on mechanical ventilation (MV).  
ccforum.com
over 4 years ago
Preview
0
0

Insulin Pumps Underused in Kids With Type 1 Diabetes

Insulin pumps are associated with better glycemic control among kids with type 1 diabetes, but are used by less than 50% of those eligible, even in some of the richest countries, and by just one in seven in the United Kingdom.  
medscape.com
over 4 years ago